Journal of Inherited Metabolic Disease

, Volume 30, Issue 3, pp 365–369 | Cite as

High incidence of autoantibodies in Fabry disease patients

Original Article


Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism that results from a deficiency of the lysosomal enzyme α-galactosidase A. This defect leads to the accumulation of its substrates, mainly globotriaosylceramide, in lysosomes of cells of different tissues. Different studies have shown the involvement of immunopathologies in different sphingolipidoses. The coexistence of FD and immune disorders such as systemic lupus erythematosus, rheumatoid arthritis and IgA nephropathy, has been described in the literature. The aim of this study was to evaluate the prevalence of a group of autoantibodies in a series of Argentine FD patients. Autoantibodies against extractable nuclear antigens (ENAs), double-stranded DNA, anticardiolipin and phosphatidylserine were assayed by ELISA. Lupus anticoagulants were also tested. Fifty-seven per cent of the samples showed reactivity with at least one autoantigen. Such reactivities were more frequent among males than among females. Antiphospholipid autoantibodies were detected in 45% of our patients. The high rate of thrombosis associated with FD could be related, at least in part, to the presence of antiphospholipid autoantibodies in Fabry patients. We found the presence of ENAs, which are a characteristic finding of rheumatological diseases, previous a frequent misdiagnosis of FD, in around 39% of the cases. The detection of a high level of autoantibodies must be correlated clinically to determine the existence of an underlying autoimmune disease. With the recent development of therapy, the life expectancy in FD will increase and autoimmune diseases might play an important role in the morbidity of FD.


Systemic Lupus Erythematosus Fabry Disease Gauche Disease Lupus Anticoagulant Gaucher_s Disease 





double-stranded DNA


extractable nuclear antigens


Fabry disease


lupus anticoagulant




Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arias Martinez N, Barbado Hernandez FJ, Perez Martin G, Perez de Ayala C, Casal Esteban V, Vazquez Rodriguez JJ (2003) Fabry’s disease associated with rheumatoid arthritis. Multisystemic crossroads. An Med Interna 20: 28–30.PubMedGoogle Scholar
  2. Beeson PB (1994) Age and sex associations of 40 autoimmune diseases. Am J Med 96: 457–462.CrossRefPubMedGoogle Scholar
  3. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry disease. N Engl J Med 276: 1163–1167.PubMedCrossRefGoogle Scholar
  4. Burstein Y, Rechavi G, Rausen AR, Frisch B, Spirer Z (1985) Association of Gaucher’s disease and lymphoid malignancy in 2 children. Scand J Haematol 35: 445–447.PubMedCrossRefGoogle Scholar
  5. Cines DB, McCrae KR (1995) The antiphospholipid-protein syndrome. J Clin Immunol 15: 86S–100S.CrossRefPubMedGoogle Scholar
  6. Costello R, O’Callaghan T, Sebahoun G (2006) Gaucher disease and multiple myeloma. Leuk Lymphoma 47: 1365–1368.CrossRefPubMedGoogle Scholar
  7. Desnick RJ, Ioannou YA, Eng CM (1995) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WX, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2741–2784.Google Scholar
  8. Eitzman DT, Bodary PF, Shen Y, et al (2003) Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 14: 298–302.CrossRefPubMedGoogle Scholar
  9. Fox H, McCarthy P, Andre-Schwartz J, Shoenfeld Y, Miller K.B (1984) Gaucher’s disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher’s disease and B-cell proliferations? Cancer 54: 312–314.CrossRefPubMedGoogle Scholar
  10. Hamers MN, Donker-Koopman WE, Coulon-Morelec MJ, Dupouey P, Tager JM (1978) Characterization of antibodies and globoside. Immunochemistry 15: 353–358.CrossRefPubMedGoogle Scholar
  11. Kint JA (1970) Fabry disease. Alpha galactosidase deficiency. Science 167: 1268–1269.CrossRefPubMedGoogle Scholar
  12. Lahita RG (1996) The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud 41: 156–165.PubMedGoogle Scholar
  13. Leslie RD, Hawa M (1994) Twin studies in auto-immune disease. Acta Genet Med Gemellol 43: 71–81.PubMedGoogle Scholar
  14. Marie JP, Tulliez M, Tricottet-Paczinski V, Reynes M, Diebold J (1982) Gaucher’s disease with monoclonal gammopathy. Significance of splenic plasmacytosis. Scand J Haematol 28: 54–58.PubMedCrossRefGoogle Scholar
  15. Marti GE, Ryan ET, Papadopoulos NM, et al (1988) Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol 29: 189–194.CrossRefPubMedGoogle Scholar
  16. McDermot KD, Holmes A, Miners AH (2001) Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750–760.CrossRefGoogle Scholar
  17. Meikle PJ, Ranieri E, Ravenscroft EM, Hua CT, Brooks DA, Hopwood JJ (1999) Prevalence of lysosomal storage disorders. JAMA 281: 249–254.CrossRefPubMedGoogle Scholar
  18. Mehta A, Ricci R, Widmer U, et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34: 236–242CrossRefPubMedGoogle Scholar
  19. Mizukami H, Mi Y, Wada R, et al (2002) Systemic inflammation in glucocerebroside-deficient mice with minimal glucosylceramide storage. J Clin Invest 109: 1215–1221.PubMedGoogle Scholar
  20. Rahman P, Gladman DD, Wither J, Silver MD (1998) Coexistence of Fabry’s disease and systemic lupus erythematosus. Clin Exp Rheumatol 16: 475–478.PubMedGoogle Scholar
  21. Rosenmann E, Kobrin I, Cohen T (1983) Kidney involvement in systemic lupus erythematosus and Fabry’s disease. Nephron 34: 180–184.CrossRefPubMedGoogle Scholar
  22. Sanchez-Guerrero J, Lew RA, Fossel AH, Schur PH. (1996) Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum 39: 1055–1061.CrossRefPubMedGoogle Scholar
  23. Simmelink MJA, Horbach DA, Derksen RHWM, et al (2001) Complexes of antiprothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 113: 621–629.CrossRefPubMedGoogle Scholar
  24. Soloninka CA, Laskin CA, Wither J, Wong D, Bombardier C, Raboud J (1991) Clinical utility and specificity of anticardiolipin antibodies. J Rheumatol 18: 1849–1855.PubMedGoogle Scholar
  25. Utsumi K, Yamamoto N, Kase R (1997) High incidence of thrombosis in Fabry’s disease. Intern Med 36: 327–329.CrossRefPubMedGoogle Scholar
  26. Whybra C, Kampmann C, Willers I (2001) Anderson–Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24: 715–724.CrossRefPubMedGoogle Scholar
  27. Whybra C, Schwarting A, Kriegsmann J, et al (2006) IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Pediatr Nephrol 21: 1251–1256.CrossRefPubMedGoogle Scholar
  28. Yamaguchi A, Katsuyama K, Nagahama K, Takai T, Aoki I, Yamanaka S (2004) Possible role of autoantibodies in the pathophysiology of GM2 gangliosides. J Clin Invest 113: 200–208.PubMedGoogle Scholar
  29. Zhao Y, Rumold R, Zhu M, et al (1999) An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 42: 2132–2138.CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer 2007

Authors and Affiliations

  1. 1.Servicio de HematologíaHospital PennaBahía BlancaArgentina
  2. 2.LISIN, Facultad de Ciencias ExactasUniversidad Nacional de La PlataPcia de Buenos AiresArgentina

Personalised recommendations